Operating income was $2.4 million, or 59% of revenue, an increase of 114% from $1.1 million, or 46% of revenue, in the third quarter of 2008.
Net income was $2.0 million, or $0.08 per share (basic and diluted), compared to a net income of $865,524, or $0.04 per share (basic and diluted), in the third quarter of 2008.
Nine months Ended September 30, 2009 Results
Net revenue was $10.1 million in the quarter ended September 30, 2009, up 30% from $7.8 million in the quarter ended September 30, 2008. Gross profit margin was 71%, which remained relatively unchanged as compared to the same period in 2008.
Operating income was $6.0 million, or 59% of revenue. Net income was $5.1 million or $0.20 per basic and fully diluted share, up 48% from $3.4 million, or $0.14 per fully diluted share in the nine-month period of 2008.
As of September 30, 2009, the Company had $230,539 in cash and cash equivalents. Kun Run generated $2.9 million in cash flow from operations in the first nine months of 2009, compared to $4.3 in the first nine months of 2008. Shareholders' equity stood at $24.0 million, with a debt to equity ratio of 0.55 at the end of September 30, 2009.
Mr. Ye Xiaoqun, Chief Executive Officer of Kun Run Biotechnology commented,
"I am satisfied with our third quarter performance, as we achieved record
revenue and solid profits. During the past nine months, Kun Run has
demonstrated success in developing and commercializing peptide medicine in the
China market and has built reputable brand awareness with superior quality.
With the extra capacity added by the newly operated facility, we
|SOURCE Kun Run Biotechnology, Inc.|
Copyright©2009 PR Newswire.
All rights reserved